Duvelisib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 221 publications

Sustained remission for mycosis fungoides following duvelisib and mogamulizumab.

Sustained remission for mycosis fungoides following duvelisib and mogamulizumab.

Journal: JAAD case reports
Published: July 19, 2026

Stereoselective ecotoxicity and environmental stability of the anticancer drug duvelisib in aquatic systems.

Stereoselective ecotoxicity and environmental stability of the anticancer drug duvelisib in aquatic systems.

Journal: Environmental pollution (Barking, Essex : 1987)
Published: May 12, 2026

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 22, 2026

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 21, 2026

Orbitrap HRMS-Based Comprehensive Metabolite Characterization of Duvelisib in Cross-Species Hepatocytes.

Orbitrap HRMS-Based Comprehensive Metabolite Characterization of Duvelisib in Cross-Species Hepatocytes.

Journal: Rapid communications in mass spectrometry : RCM
Published: April 10, 2026

Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database.

Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database.

Journal: Clinical therapeutics
Published: March 18, 2026

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Journal: Blood advances
Published: January 29, 2026

Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.

Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.

Journal: Analytical methods : advancing methods and applications
Published: January 26, 2026

Targeting PI3Kδ for lymphoma and immune diseases treatment: a review.

Targeting PI3Kδ for lymphoma and immune diseases treatment: a review.

Journal: Molecular diversity
Published: January 20, 2026

Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.

Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.

Journal: Cureus
Published: December 26, 2025

Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.

Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.

Journal: American journal of clinical dermatology
Published: December 01, 2025

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Journal: Biochemical and biophysical research communications
Published: December 01, 2025
Showing 1-12 of 221

Last Updated: 09/26/2026